Medicare Opens the Door to Weight-Loss Drugs at $50 a Month, and to a Fight Over the Bill

For more than twenty years a statutory quirk kept Medicare from paying for medicines to treat obesity, even as the same drugs reshaped clinical practice and household budgets across the country. On July 1 that arrangement changed. A temporary program can now hand eligible seniors a supply of the most sought-after weight-loss injections for a flat $50 a month, and at the same moment a well-funded chorus of critics is asking who really gains from the deal and how long it can last. Both propositions are true, and the tension between them defines the policy.

The vehicle is the Medicare GLP-1 Bridge, a demonstration run by the Centers for Medicare and Medicaid Services. It marks the first time the program has covered prescription drugs specifically for weight reduction, and it arrives wrapped in caveats about duration, eligibility and the arithmetic underneath the copay.

Bridge program terms, spelled out

The mechanics are straightforward for beneficiaries and considerably less so behind the counter. Eligible enrollees pay $50 a month, and that figure holds regardless of dose escalation, an important detail given that GLP-1 regimens typically titrate upward over time. Three products qualify, according to CMS materials and reporting by NPR and KFF:

• Wegovy, the semaglutide product from Novo Nordisk, available in both injectable and tablet forms.
• Zepbound, Eli Lilly's tirzepatide injection.
• Foundayo, an orforglipron product, an oral entrant that broadens the menu beyond injectables.

The program runs from July 1, 2026 through December 31, 2027, and it operates outside the normal Part D benefit and payment flow. CMS selected Humana as the central claims processor. Under the arrangement described by CMS, pharmacies collect the $50 copay and Humana reimburses them at the wholesale acquisition cost of the drug, less the copay, plus a dispensing fee. Notably, the $50 payments do not count toward a beneficiary's Part D deductible or the out-of-pocket spending cap, a structural wrinkle that keeps the Bridge walled off from the rest of the benefit.

Eligibility, and the numbers

Access is gated by clinical criteria and prior authorization rather than offered to all comers. Enrollees must be in a standalone prescription drug plan or a Medicare Advantage plan with drug coverage, and they must clear thresholds tied to body mass index and comorbid conditions. The criteria reported from CMS guidance include:

• A BMI of 35 or greater.
• A BMI of 30 or greater accompanied by heart failure, uncontrolled hypertension or chronic kidney disease.
• A BMI of 27 or greater with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

The addressable population is large. KFF estimated that nearly 3.8 million Part D enrollees would have met the eligibility criteria based on 2023 data, a figure that hints at both the pent-up demand and the potential fiscal exposure the program carries.

Competing claims over cost

Here the framing splits. Supporters present the Bridge as overdue relief for a chronic disease that Medicare had long treated as uniquely undeserving of coverage, and as a source of real data on utilization that could inform durable policy. Skeptics, including some who scrutinize the drugmakers' incentives, read the same facts as a windfall for manufacturers dressed as consumer relief.

That skepticism has a specific target. STAT reported that the Trump administration negotiated a $245 monthly price for the drugs in Medicare and Medicaid, contingent on private insurers covering all uses at a $50 copay, a condition that was not publicly disclosed at the outset. STAT characterized the structure as a volume-for-discount exchange in which, by its account, the companies in some cases secured higher sales volume without delivering correspondingly lower prices. As the outlet put it:

Lower prices in exchange for higher sales volume. Instead, the companies secured higher volume without the lower prices in some cases.

For Novo Nordisk and Eli Lilly, whose franchises anchor the category, expanded Medicare access enlarges the market at precisely the moment competition and pricing pressure have intensified. The Bridge does not resolve the question at the center of the dispute, namely whether taxpayers are buying access at a fair price or subsidizing demand at a generous one.

Temporary by design, not permanent

The program's name is a tell. The Bridge was conceived as a stopgap ahead of a more permanent financing framework, the BALANCE model, intended to fold GLP-1 coverage into Part D on a lasting basis. That larger plan stalled. Reporting indicated that CMS postponed the BALANCE pilot after major insurers, including CVS and UnitedHealth Group, balked at the financial strain of participating, prompting the agency to substitute the time-limited Bridge instead.

The improvised quality of the solution creates its own problems. Chronic conditions are not usually managed on a countdown clock, yet the Bridge is scheduled to expire at the end of 2027. Clinicians have flagged the risk of an abrupt coverage cliff, a scenario in which patients who respond well to therapy lose access when the demonstration lapses. Because these drugs tend to reverse their benefits once discontinued, a coverage gap is not a neutral pause but a clinical setback. Other frictions loom as well:

• Prior authorization requirements that can delay or deter eligible patients.
• Uneven awareness of the program among beneficiaries who might qualify.
• Divergent decisions among pharmacy benefit managers, with at least one major player having moved to exclude one of the covered drugs from its commercial formularies.

Milestone, with asterisks

None of the caveats erases the significance of the moment. Medicare's decades-long exclusion of obesity medicines had grown increasingly difficult to defend as the evidence accumulated that GLP-1 therapies reduce weight and, in several populations, cardiovascular and kidney risk. The Bridge concedes that point in practice, offering a concrete benefit to a defined group of seniors at a predictable price.

Whether it becomes a durable feature of the program or a two-year experiment remembered chiefly for its financing dispute will depend on what CMS learns from utilization data, how the drugs perform on cost over time, and whether the political appetite exists to make coverage permanent once the demonstration ends. For now, eligible enrollees have something they did not have on June 30, a covered path to treatment. The argument over what that path costs, and who profits from it, has only just been joined.

This account draws on CMS program materials and reporting by NPR, KFF, STAT and BioSpace, and is a draft prepared for editorial verification.